Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Alsius Corporation (the "Company") is filing this report on Form 8-K to report the following event under Items 5.02(c) & (e):

On July 24, 2008, Gregory J. Tibbitts was engaged by the Company on a consulting basis, and will begin functioning as its Chief Financial Officer after the upcoming departure of Brett Scott, the Company's current Chief Financial Officer. Mr. Tibbitts' consulting agreement with the Company runs through March 31, 2009, unless extended, and provides for per diem compensation of $1,250 and additional bonus payments of $50,000 to $150,000 upon achievement of certain corporate goals.

Mr. Tibbitts, 41, served as the Chief Financial Officer of Cryocor, Inc., a medical device company focused on cardiology, from July 2004 until its acquisition by Boston Scientific Corporation in May 2008. From April 2000 to June 2004, Mr. Tibbitts held various positions, including Chief Financial Officer, with Elitra Pharmaceuticals Inc., a biotechnology company. From December 1996 to March 2000, Mr. Tibbitts was a senior manager in the audit department of Ernst & Young LLP, specializing in the biotechnology, medical device and other high technology industries. Mr. Tibbitts received a B.A. in Business Administration from the University of San Diego and an M.B.A. in Finance from San Diego State University, and is a Certified Public Accountant in the State of California.

-2-

---